Anti-Angiogenic Retinal Therapy
The Age-Related Macular Degeneration (AMD) complicated with Sub-Retinal Neo-Vascularization of sub-foveolar location it is responsible for 90% of cases of blindness and irreversible loss of central vision and for which the traditional treatment was only aimed at halting the process of neo-vascular proliferation, through thermal laser photocoagulation, which resulted in the destruction of different layers of the retina, causing immediate and irreversible loss of central vision.
Currently, this disease is treated in a more specific and an even less harmful way for healthy retinal cells and structures, through the administration of Anti-Angiogenic drugs by Intra-Vitreous Injection. These injections are performed at IMO as an outpatient treatment under topical anesthesia, exclusively done in the operating room.
With these new therapies for Age Related Macular Degeneration (AMD) it is possible to not only preserve visual acuity, but in many cases to achieve some improvement in vision, especially when detected early and treatment performed in a timely manner.
With these new therapies for Age Related Macular Degeneration (AMD) it is possible to not only preserve visual acuity, but in many cases to achieve some improvement in vision, especially when detected early and treatment performed in a timely manner.
In addition to Age-Related Macular Degeneration, anti-angiogenic therapy is also used in situations that are associated with Sub Retinal Neo-Vascularization (referred to as High Myopia and Traumatic or Degenerative Pathology) and some Retinal Vascular Diseases, such as Diabetic Retinopathy and Retinal Venous Occlusions.
